“If we have a surplus, we’re going to share it with the rest of the world,” Mr. Biden told reporters Wednesday, generally speaking about American vaccine supplies. “We’re starting to make sure Americans get noticed first.”
Johnson & Johnson, which has authorization for the vaccine in the United States, but lagged behind its production targets in both the United States and Europe, recently asked the United States to loan 10 million doses to the European Union , But the Biden administration also refused that request, according to American and European officials.
The European Union has come under severe criticism for “vaccine nationalism” and protectionism, which intensified in Italy last week. A small dose of dose blocked for Australia, Taking a tug of war on badly needed shots. Nevertheless, the European Union Exported 34 million doses Coronoviruses have been vaccinated in dozens of countries in recent weeks, even at home.
As disappointments boil over, some European officials are blaming the United States. President of the European Council, Charles Mitchell, The United States, along with Britain, said, “Has imposed a similar ban on the export of vaccines or vaccine components produced on its territory.” White House press secretary Jane Sasaki told reporters Thursday about the US supply of the AstraZeneca vaccine to meet the terms of its contracts with the government, as well as to export its products made in the United States Were independent.
But because AstraZeneca was produced with the help of vaccines Defense production act, Mr. Biden has to approve dose shipments overseas. Such a move could lead to huge negative political consequences as long as Americans are still struggling for shots.
AstraZeneca also seeks liability protection for doses shipped overseas, such as when vaccines are approved in the United States.
Meanwhile, regulators in the United States are waiting for new AstraZeneca data, over the next few weeks, A 3 phase test That 32,000 participants are mostly enrolled in the United States. AstraZeneca is unlikely to report results from an early glance at its data, as other vaccine manufacturers have done. Federal officials will instead have to wait for more statistical results because trial participants are monitored for longer periods of side effects and more people in the vaccine and placebo groups may become ill, federal officials said. Experts believe that the vaccine is unlikely to carry a higher efficacy rate than the one shot by Johnson & Johnson, which uses a similar technology and requires only one dose.